UrgoStart significantly improves patients’ quality of life

News & Event

UrgoStart significantly improves patients’ quality of life

 UrgoStart significantly improves patients’ quality of life (1)

JWC logo

Over 200 days: this is the average healing time for patients suffering from a leg ulcer. Beyond their cost burden, such wounds have a strong impact on patients’ health-related quality of life (HRQoL). During months, patients endure restricted mobility; they suffer from pain, anxiety, stress and even depression. The critical need to address such HRQoL impairments is recognized by guidelines and healthcare professionals, together with the priority of reduced healing time.


At Urgo Medical, our mission is to develop innovative solutions to help healthcare professionals reduce healing time and improve patients’ quality of life.


Urgo Medical is proud to announce the second publication of Challenge study, in which the results are being reported with a specific zoom on UrgoStart’s impact on patients’ QoL(1).


The Challenge study is the first double-blind RCT conducted in wound care field, providing for a dressing, the proof of higher healing properties. It has demonstrated that UrgoStart accelerates healing of venous and mixed leg ulcers, as compared to a neutral dressing.


Following a first publication in 2012(2), the results of the Challenge study are reported in this second publication(1) with a specific assessment of UrgoStart’s  impact on patient’s Quality of Life: it has been demonstrated that UrgoStart significantly reduces pain/discomfort and anxiety/depression, as compared to the control group, among patients suffering from venous and mixed leg ulcers.


Therefore, UrgoStart significantly improves patients’ quality of life.


Recently, Urgo Medical had also published the results of REALITY analysis(3): it has been observed in over 10,000 patients in daily practice that UrgoStart reduces healing time by 100 days on average, and such results in real-life were consistent with RCT results.


UrgoStart, with its unique protease-modulating matrix (TLC-NOSF), continues to accumulate evidence supporting its superior efficacy as compared to a neutral dressing.


Because we know that every day without a wound really makes a difference for patients, we work every day to reduce healing time.


To read the full publication: JWC – Quality of Life in patients with Leg Ulcer – Challenge RCT


To discover the publication on REALITY: JoWC_2017_26_2_S4_S15_Bohbot_Web

 (1) Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.
(2) Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.
(3) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153
Last update : February 28, 2021